Prof. Paulo Eduardo Stanga

Prof. Paulo Eduardo Stanga

The Retina Clinic London – Director

London Vision Clinic – Retina Lead & Vitreoretinal Surgeon

Institute of Ophthalmology, University College London

Medical & Surgical Retina, Macular Degeneration, Diabetic Retinopathy, Vitreous Floaters, Cataracts, Retinal Laser, R&D New Therapies, Surgical Technology, Advanced Imaging & Clinical Studies

Experience: over 31 years in Ophthalmology and 21 years in the NHS.

Left the NHS & University of Manchester in 2019.

Clinical, Surgical and R&D activities: The Retina Clinic London and the London Vision Clinic.

Since 1993: Development/application of new outpatient & surgical therapies & technologies.

Principal Investigator (PI) on industry-sponsored trials & Scientific Advisor to commercial companies developing pharmacological/surgical therapies, diagnostic/therapeutic equipment.

Good Clinical Practice: Certified. Experimental Animal Lab Surgery: Licensed.

Notable achievements: Introduced Optical Coherence Tomography (OCT) into clinical setting (UK, 1998), Pascal® Laser (EU, 2006), pioneered Optos® Ultra Wide-Field Imaging (Intl., 2006) & introduced Swept-Source OCT (EU, 2012) as well as Wide-Field OCT (Intl. 2019).

Developed new Hypersonic Vitrectomy technology for Bausch and Lomb Health from lab bench (2012) to FDA 510(k) clearance, First-in-Human (2017) and EU introduction (2018). Set-up, PI and Surgeon for a the First-in-Human Study of Artificial Vision and the Argus II in Age-Related Macular Degeneration (AMD). Successfully implanted first-ever electronic retinal implants in AMD. Pivotal role for NHS England to fund & evaluate Argus II in Retinitis Pigmentosa (RP) & its 1st use of Artificial (2016). Performed first Argus II implantations in RP in several countries and set up artificial vision programs with which he continues to collaborate, i.e., Russia.

Former UK CI and local Principal Investigator (PI) and Surgeon in a Gene Therapy Study in RP (RPGR) (Nature Medicine, 2020).

Performed First-Ever Gene Therapy surgery in the UK Independent Sector (Clinical Study) in Geographic Atrophy in Dry AMD (2020).

Current Clinical Studies: Gene Therapy Surgery and Anti-Complement lntravitreal lnjections in Advanced Dry AMD with Geographic Atrophy, Laser Ablation and Limited Vitrectomy of Vitreous Floaters and Management of Vision Degrading Myodesopsia, Wide Field OCT and Ultra-Wide Field Vitreo-Retinal lmaging.

Actively publishes in peer-reviewed scientific journals: H-Index 35. ORCID iD: https://orcid.org/0000-0002-3338-2055.

Several international accolades, amongst others; prestigious Achievement Award/American Academy of Ophthalmology (AAO).